TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06095089: A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 355 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$5,403,552

Rescue Site Savings

+$3,581,424

Unlock Full NCT06095089 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06095089 Rescue Dossier →